EU Fast Track Sought For Alzheimer’s, Hemophilia & Multiple Myeloma Drugs

 
• By Neena Brizmohun

Lecanemab, which could be approved in the US this week for Alzheimer’s disease, is among the latest investigational products that the European Medicine Agency has considered for review under its accelerated assessment pathway.

Sprint finish
Companies have asked for their marketing applications to be reviewed faster • Source: Shutterstock

More from Europe

More from Geography